How To Distinguish Real Moats from Timing Advantages In Technology Due Diligence
Most M&A technology diligence confirms what the deal team already believes. That is not a moat assessment.
The question that doesn’t get asked
Every deal involving a technology-intensive asset carries a version of the same question. The question almost never gets answered properly.
It is not: Does this technology work?
That question gets answered. Technical due diligence, vendor references, demo environments, architecture walkthroughs — deal teams and external experts are competent at confirming that the technology functions. That is not where the failure occurs.
The question that doesn’t get asked is different:
Does this technology survive a well-funded competitor allocating an 18-month engineering sprint?
That is a moat question. It has nothing to do with whether the product works. It has everything to do with whether the product’s underlying architecture contains structural barriers to replication — or whether what looks like differentiation is actually a timing advantage that erodes the moment someone else decides to build.
Most deal teams do not ask this question because they conflate two things that feel similar but are structurally distinct: comprehension difficulty and replicability difficulty. The technology is hard to understand, therefore it must be hard to replicate. That inference is wrong more often than it is right.
And when it is wrong, the deal prices a moat that does not exist.
What “moat” actually means in a deal context
In technology M&A and growth-stage investment, the word “moat” is used casually and almost never decomposed. It functions as a confidence marker — the deal team believes the technology is differentiated, and the word “moat” signals that belief to the investment committee without requiring a structured assessment of what kind of differentiation exists and how long it holds.
That is insufficient.
The question that matters is not only whether the technology is differentiated. It is what kind of differentiation you are actually looking at — and how long it survives contact with a well-resourced competitor.
Some technology positions are structurally defended. The architecture depends on inputs a competitor cannot access — proprietary data generated through years of deployment, infrastructure that cannot be replicated without regulatory or physical preconditions, or methods whose value lies not in the engineering but in the accumulated learning embedded within them. That kind of advantage degrades slowly, if at all.
Other technology positions are well-executed but architecturally replicable. The team did excellent work. The product functions. But the underlying stack is available, the patterns are known, and any competent team with equivalent capital could rebuild the core in 12 to 24 months. That is not a moat. That is a timing advantage — one that looks like differentiation today because no one else has done the work yet. It stops looking like differentiation the moment someone starts.
Still others are positioned through commercial momentum rather than architectural novelty. The advantage is real, but it lives in integrations, customer relationships, brand, or market position — not in the technology itself. That is a different asset class than what a “technology moat” typically implies.
These distinctions produce radically different valuations, risk profiles, and competitive exposure windows. The word “moat” collapses them into one. That is not simplification. It is a pricing error.
The distinction matters because the people closest to the technology — the founders, the CTO, the internal champion, the deal sponsor — have every structural incentive to frame engineering competence as proprietary advantage. That is not dishonesty. It is perspective. The person who built the architecture genuinely believes it is differentiated, because from their vantage point, it is. They experienced the difficulty of building it. What they cannot see is whether that difficulty is structural or merely sequential — whether a competitor would face the same barriers, or simply needs to start.¹
An independent assessment exists precisely to answer that question from outside the deal’s own conviction.
The case
A venture capital fund evaluating a Series B investment in an industrial technology platform requested an independent technology defensibility assessment. The target had built a proprietary data processing architecture for industrial sensor networks and claimed a 3-to-5-year replicability barrier. The fund needed a structured recommendation before the investment committee meeting.
The deal team had strong commercial conviction. Growing TAM. Sticky enterprise customers. A founder team with deep domain expertise. The technology claims were not challenged — they were commercially opaque. The target’s pitch positioned their edge-computing architecture as “unique” and “patent-protected,” but the fund lacked the internal capability to verify whether the architecture was genuinely novel or a well-packaged integration of open-source components with standard cloud orchestration.
The core question was binary: Does this technology represent a structural moat — or a timing advantage that erodes once a well-funded competitor allocates an 18-month engineering sprint?
The assessment
The work started with decomposition — not of the business model, but of the architecture itself.
The target’s system was broken into five functional layers: data ingestion, edge processing, protocol translation, analytics engine, and API layer. Each layer was mapped against publicly available alternatives, open-source equivalents, and competing commercial implementations. The question was not whether each layer worked. The question was whether each layer was structurally defended or merely well-executed.²
That distinction requires more than domain expertise. It requires a specific analytical discipline for each layer:
What would it cost a well-resourced competitor — in time, talent, and capital — to replicate it independently?
Which layers carry regulatory, data-network, or switching-cost barriers that cannot be shortcut?
And which layers are protected only by the fact that no one has attempted the work yet?
The findings were then translated into the variables the investment committee actually needed: a moat duration estimate, a competitive exposure window, and the specific technical risks that should be priced into the valuation.
What we found
3 of 5 architectural layers were replicable using open-source frameworks and reverse-engineering by seasoned experts within 12 to 18 months.
The remaining 2 layers — a proprietary protocol translation engine and a sensor-specific data normalization pipeline — represented genuine IP with an estimated 3+ year replicability barrier. But that barrier held only in combination with the target’s accumulated training data from 400+ industrial deployments.
The moat was real. It was also narrower than the target claimed — and structurally dependent on continued data accumulation velocity. If a competitor secured comparable deployment access, the barrier would compress to approximately 18 months.
This is the finding that matters: the moat was not binary. It was conditional. And the condition — sustained data velocity advantage — was itself contingent on commercial execution, not on architectural novelty.
Without decomposition, the deal team would have priced a 3-to-5-year moat. With decomposition, they priced a narrower, contingent advantage that required specific commercial conditions to hold.
The investment translation
The fund proceeded with the investment at a repriced valuation reflecting the narrower-than-claimed moat.
That is the outcome of doing this correctly. Not a killed deal. Not a dramatic reversal. A repriced deal with full risk transparency. The investment committee made a decision with structural clarity about what they were buying: genuine IP in two layers, engineering competence in three, and a moat duration that depended on commercial velocity rather than architectural lock-in.
The pattern
This is not an edge case.
Every technology-intensive deal — industrial platforms, AI systems, life sciences instruments, advanced materials processes, cleantech architectures, complex software stacks — carries a version of the same structural question. The technology has multiple layers. Some layers are genuinely proprietary. Others are engineering competence on available infrastructure. The deal team’s conviction about the technology is almost always built on comprehension difficulty, not on a structured assessment of replicability.
That conflation is the failure mode. It is quiet, it is structural, and it repeats across sectors.
BCG and Hello Tomorrow documented the broader pattern: deep tech’s growing share of venture capital still represents only around 20% of VC funding, up from roughly 10% a decade ago, precisely because the structural complexity of these technologies resists the evaluation frameworks optimized for software-like investments.³ McKinsey’s analysis of technology-intensive ventures identifies the “valleys of death” in financing — the phases between discovery and proof of concept, and again between pilot validation and commercial deployment — where traditional diligence frameworks consistently misread structural complexity as execution risk.⁴
The moat confusion is a specific instance of a broader misclassification problem: when the people evaluating the technology lack assessment discipline specific to the architecture, they substitute narrative confidence for structural verification. The vendor evaluates itself. The deal sponsor validates their own thesis. The investment committee receives conviction rather than decomposition.⁵
What follows from this
If you are pricing a technology-heavy deal, someone in the process needs to decompose the architecture. Not describe it. Decompose it.
That means classifying each layer by defensibility type. It means stress-testing each layer against a funded competitor scenario. It means distinguishing structural barriers from timing advantages. And it means translating the findings into variables the investment committee can actually price — moat duration, competitive exposure, and the specific conditions under which the moat holds or degrades.
This is not complex work. It is structured, repeatable, and takes days, not months. Architecture decomposition, replicability analysis, competitive landscape mapping against the specific technology claim — this is a discipline, not a mystery.
The cost of not doing it is a wrong multiple on every technology-heavy deal that passes through your committee without this layer.
Most deal teams do not skip this step because they reject its value. They skip it because no one in the process is assigned to do it.
That is a structural gap. And it has a price.
¹ This is the structural logic behind what I call “The Vendor Evaluates Itself” — the observation that the people closest to the technology are invaluable for understanding it but structurally unable to assess it independently. Independence is not about expertise. It is about incentive alignment.
² Arise Innovations’ applied research applies a proprietary multi-dimensional assessment framework, validated by the German Federal Ministry of Research, Technology and Space (BMFTR), developed through 250+ cases across 25+ ecosystems.
³ BCG & Hello Tomorrow, “The Deep Tech Investment Paradox” (2021); BCG, “The Dawn of the Deep Tech Ecosystem” (2019). Deep tech’s share of VC has grown but remains structurally underweighted relative to its economic and societal impact potential.
⁴ McKinsey & Company, “Investing in deep tech” and related analysis on financing “valleys of death” in technology-intensive ventures.
⁵ For a full treatment of how language and misclassification produce downstream decision errors in technology evaluation, see: M.K. Witte, “Terminology, Misclassification, and Decision Errors in Deep Tech,” The Arise Vault (2026).